SUSVIMO

Ranibizumab · Genentech, Inc.

Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for SUSVIMO, covering 2021-10-22 to 2026-07-24. Get the full timeline:

Most recent: New treatment option for neovascular age-related macular degeneration